| scholarly article | Q13442814 |
| P50 | author | C Simon Herrington | Q57020021 |
| Brooke E Howitt | Q57106122 | ||
| Blaise A Clarke | Q60683603 | ||
| Xavier Matias-Guiu Guia | Q62016438 | ||
| Kathleen Cho | Q69939385 | ||
| Anais Malpica | Q69964105 | ||
| Philip Ip | Q71442328 | ||
| Glenn Mccluggage | Q87853541 | ||
| Esther Oliva | Q124080506 | ||
| P2093 | author name string | Ie-Ming Shih | |
| Teri A Longacre | |||
| August Vidal | |||
| Pei Hui | |||
| Sabrina Croce | |||
| Kumarasen Cooper | |||
| Patricia Shaw | |||
| Sigurd Lax | |||
| Bradley J Quade | |||
| Vinita Parkash | |||
| Anna Yemelyanova | |||
| Lora Hedrick Ellenson | |||
| Bojana Djordevic | |||
| Martin Koebel | |||
| P2860 | cites work | Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers | Q28257103 |
| POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer | Q28260529 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 | Q28265132 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist | Q34008620 | ||
| p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. | Q53061462 | ||
| Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. | Q53551125 | ||
| POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. | Q54351302 | ||
| Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. | Q54740192 | ||
| Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. | Q55070868 | ||
| ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up | Q57903637 | ||
| Microsatellite Instability and Epigenetic Inactivation ofMLH1and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type | Q60369064 | ||
| L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results | Q63199178 | ||
| Methylation of hMLH1 in a population-based series of endometrial carcinomas | Q74352335 | ||
| Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients | Q80050907 | ||
| Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel | Q84452748 | ||
| Decreased hyaluronidase 1 expression is associated with early disease recurrence in human endometrial cancer | Q86521508 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q86680661 | ||
| Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma | Q34354361 | ||
| Cancer risk in mutation carriers of DNA-mismatch-repair genes | Q34502900 | ||
| Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations | Q34959257 | ||
| Prognostic significance of POLE proofreading mutations in endometrial cancer. | Q34994583 | ||
| Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer | Q35181103 | ||
| Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing | Q35235483 | ||
| DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer | Q35603652 | ||
| Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. | Q35748591 | ||
| ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors | Q35836542 | ||
| A clinically applicable molecular-based classification for endometrial cancers | Q35863143 | ||
| Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma | Q36637663 | ||
| Hormone therapy in advanced and recurrent endometrial cancer: a systematic review | Q36794868 | ||
| Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome | Q37215983 | ||
| Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis | Q37221791 | ||
| Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers | Q37288374 | ||
| Resistance to chemotherapy and hormone therapy in endometrial cancer | Q37384527 | ||
| Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome | Q37399783 | ||
| Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab | Q37470078 | ||
| Use of mutation profiles to refine the classification of endometrial carcinomas. | Q37612253 | ||
| A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas | Q37866075 | ||
| Endometrial carcinoma: molecular alterations involved in tumor development and progression | Q37994980 | ||
| Prognostic biomarkers in endometrial and ovarian carcinoma | Q38185940 | ||
| Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations | Q38267985 | ||
| Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma | Q38396999 | ||
| L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). | Q40009522 | ||
| L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. | Q40629455 | ||
| Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study. | Q40784062 | ||
| Improved survival of patients with hypermutation in uterine serous carcinoma | Q41024344 | ||
| Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy | Q42380793 | ||
| Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial | Q43528769 | ||
| Molecular diagnosis of endometrial cancer from uterine aspirates. | Q44593249 | ||
| Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors | Q44827392 | ||
| Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers | Q44846715 | ||
| L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. | Q45959051 | ||
| Immunotherapy in Endometrial Cancer: In the Nick of Time | Q48549392 | ||
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative | Q49158742 | ||
| Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. | Q51063696 | ||
| Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. | Q51065192 | ||
| Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. | Q51113485 | ||
| Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. | Q51552333 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endometrial cancer | Q944777 |
| gynaecology | Q1221899 | ||
| obstetrics | Q5284418 | ||
| P304 | page(s) | S114-S122 | |
| P577 | publication date | 2018-03-08 | |
| P1433 | published in | International Journal of Gynecological Pathology | Q15746551 |
| P1476 | title | International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. | |
| P478 | volume | 38 Suppl 1 |
Search more.